Avadel Pharmaceuticals Welcomes Kevin Springman as VP of Sales
Avadel appoints Kevin Springman as VP of Sales to drive LUMRYZ’s growth in the sleep medicine market.
Avadel Pharmaceuticals has named Kevin Springman as its new Vice President of Sales, bringing over 25 years of industry expertise to the role. Known for his leadership in rare disease drug launches and commercial strategy, Springman’s appointment comes at a crucial time as Avadel expands the market presence of LUMRYZ™, its FDA-approved narcolepsy treatment. CEO Greg Divis praised Springman’s proven ability to build and lead specialized sales teams, emphasizing his role in unlocking LUMRYZ’s billion-dollar potential.
Springman, who has held executive positions at AstraZeneca, Sobi, and Albireo Pharma, expressed excitement about shaping Avadel’s commercial success. He aims to optimize sales strategies and ensure LUMRYZ reaches more patients in need of improved sleep disorder treatments. With ongoing advancements, including a Phase 3 trial in idiopathic hypersomnia (IH), Avadel is poised to lead the sleep medicine space, and Springman’s expertise will be key to that growth.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion